Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Mark I. Cockett"'
Autor:
Chunfu Wang, Haichang Huang, Kirsten Mallon, Lourdes Valera, Kyle Parcella, Mark I. Cockett, John F. Kadow, Eric P. Gillis, Mark Krystal, Robert A. Fridell
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
GSK878 is a newly described HIV-1 inhibitor that binds to the mature capsid (CA) hexamer in a pocket originally identified as the binding site of the well-studied CA inhibitor PF-74. Here, we show that GSK878 is highly potent, inhibiting an HIV-1 rep
Autor:
Zhufang Li, Peter Ackerman, Nannan Zhou, Margaret Gartland, Max Lataillade, Mark I. Cockett, Rose Ronald, Mark Krystal, Jagadish Beloor
Publikováno v:
AIDS (London, England)
Background: Temsavir (TMR), the active agent of the gp120-directed attachment inhibitor fostemsavir (FTR), the CD4-directed attachment inhibitor ibalizumab (IBA), and the CCR5 antagonist maraviroc (MVC) are antiretroviral agents that target steps in
Autor:
Scott Balsitis, Volodymyr Gali, Pamela J Mason, Susan Chaniewski, Steven M Levine, Michael J Wichroski, Michael Feulner, Yunling Song, Karen Granaldi, James K Loy, Chris M Thompson, Jacob A Lesniak, Catherine Brockus, Narendra Kishnani, Stephan Menne, Mark I Cockett, Renuka Iyer, Stephen W Mason, Daniel J Tenney
Publikováno v:
PLoS ONE, Vol 13, Iss 2, p e0190058 (2018)
Immune clearance of Hepatitis B virus (HBV) is characterized by broad and robust antiviral T cell responses, while virus-specific T cells in chronic hepatitis B (CHB) are rare and exhibit immune exhaustion that includes programmed-death-1 (PD-1) expr
Externí odkaz:
https://doaj.org/article/86a83d2c3bb74090986d3dcb2cb37f05
Autor:
Tricia Protack, Sing-Yuen Sit, Dieter M. Drexler, Alicia Regueiro-Ren, Mark I. Cockett, Yan Chen, Jerry Jeffrey, Nicholas A. Meanwell, Joseph L. Cantone, Ira B. Dicker, Martin Gartland, Mark Krystal, Zeyu Lin, Brian McAuliffe
Publikováno v:
Antimicrobial Agents and Chemotherapy
HIV-1 maturation inhibitors (MIs) offer a novel mechanism of action and potential for use in HIV-1 treatment. Prior MIs displayed clinical efficacy but were associated with the emergence of resistance and some gastrointestinal tolerability events. Tr
High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus.
Autor:
Michael J Wichroski, Jie Fang, Betsy J Eggers, Ronald E Rose, Charles E Mazzucco, Kevin A Pokornowski, Carl J Baldick, Monique N Anthony, Craig J Dowling, Lauren E Barber, John E Leet, Brett R Beno, Samuel W Gerritz, Michele L Agler, Mark I Cockett, Daniel J Tenney
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e42609 (2012)
The recent development of a Hepatitis C virus (HCV) infectious virus cell culture model system has facilitated the development of whole-virus screening assays which can be used to interrogate the entire virus life cycle. Here, we describe the develop
Externí odkaz:
https://doaj.org/article/c696c60727114ef3a6359c336e98b64f
Autor:
Alicia Regueiro-Ren, Jacob J. Swidorski, Zheng Liu, Yan Chen, Ny Sin, Sing-Yuen Sit, Jie Chen, Brian L. Venables, Juliang Zhu, Beata Nowicka-Sans, Tricia Protack, Zeyu Lin, Brian Terry, Himadri Samanta, Sharon Zhang, Zhufang Li, John Easter, Brett R. Beno, Vinod Arora, Xiaohua S. Huang, Sandhya Rahematpura, Dawn D. Parker, Roy Haskell, Kenneth S. Santone, Mark I. Cockett, Mark Krystal, Nicholas A. Meanwell, Susan Jenkins, Umesh Hanumegowda, Ira B. Dicker
Publikováno v:
Journal of Medicinal Chemistry. 61:7289-7313
Autor:
Max Lataillade, Samit R Joshi, Brett R. Beno, Ira B. Dicker, Mark Krystal, Sharon Zhang, Neelanjana Ray, Mark I. Cockett, Alicia Regueiro-Ren
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 10, p e0224076 (2019)
PLoS ONE, Vol 14, Iss 10, p e0224076 (2019)
GSK3532795 (formerly BMS955176) is a second-generation maturation inhibitor (MI) that progressed through a Phase 2b study for treatment of HIV-1 infection. Resistance development to GSK3532795 was evaluated through in vitro methods and was correlated
Autor:
Carl J Baldick, Michael J Wichroski, Annapurna Pendri, Ann W Walsh, Jie Fang, Charles E Mazzucco, Kevin A Pokornowski, Ronald E Rose, Betsy J Eggers, Mayla Hsu, Weixu Zhai, Guangzhi Zhai, Samuel W Gerritz, Michael A Poss, Nicholas A Meanwell, Mark I Cockett, Daniel J Tenney
Publikováno v:
PLoS Pathogens, Vol 6, Iss 9, p e1001086 (2010)
Small molecule inhibitors of hepatitis C virus (HCV) are being developed to complement or replace treatments with pegylated interferons and ribavirin, which have poor response rates and significant side effects. Resistance to these inhibitors emerges
Externí odkaz:
https://doaj.org/article/1ee8b0be7b894e5398d932dbcf2e4866
Autor:
Rui-Ru Ji, Heshani de Silva, Yisheng Jin, Robert E Bruccoleri, Jian Cao, Aiqing He, Wenjun Huang, Paul S Kayne, Isaac M Neuhaus, Karl-Heinz Ott, Becky Penhallow, Mark I Cockett, Michael G Neubauer, Nathan O Siemers, Petra Ross-Macdonald
Publikováno v:
PLoS Computational Biology, Vol 5, Iss 9, p e1000512 (2009)
The dose response curve is the gold standard for measuring the effect of a drug treatment, but is rarely used in genomic scale transcriptional profiling due to perceived obstacles of cost and analysis. One barrier to examining transcriptional dose re
Externí odkaz:
https://doaj.org/article/2200014703f348538cb5cd6ad646b99a
Autor:
Guangzhi Zhai, Kevin A. Pokornowski, Hua Fang, Betsy J. Eggers, Melissa Kramer, Ramkumar Rajamani, Carl J. Baldick, Mark I. Cockett, Nicholas A. Meanwell, Eric Mull, Daniel J. Tenney, Susan Jenkins, Paul Michael Scola, Li-Qiang Sun, Ying-Kai Wang, Zhao Qian
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 27:1089-1093
A series of potent and novel acylsulfonamide-bearing triazines were synthesized and the structure-activity relationships (SARs) as HCV entry inhibitors were evaluated. This acylsulfonamide series was derived from an early lead, 4-(4-(1-(4-chloropheny